Skip to main content
OpenTrials
Completed

NCT Number: NCT04209946

Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants

This study is being conducted to determine whether prophylactic administration of surfactant by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical ventilation in the first 72 hours of life when compared to early Continuous Positive Airway Pressure (CPAP) alone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

24 week–29 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California, Irvine, Irvine, California, United States

Loading trial locations.

About this study

In order to allow for initial stabilization on CPAP, infants will be randomized by 1 hour of life. Consented infants that are assessed by a provider as clinically stable (i.e. HR> 100 bpm) and spontaneously breathing on CPAP will be randomized by computer generated randomization cards placed in opaque envelopes.

Randomization will be stratified by gestational age (24-26+6 weeks and 27-29+6 weeks) and labeled as such on each envelope. Multiples will be randomized to the same treatment group for ease of consent and family considerations.

Infants randomized to LISA will receive surfactant (Curosurf 2.5 mL/kg, based on estimated fetal weight) and must be given in the first 2 hours of life using a conventional or video laryngoscope and a small flexible 16 gauge angiocatheter.

All sites have agreed on using senior level physicians or practitioners that have prior experience with the LISA method. An orogastric tube will be placed into the stomach prior to laryngoscopy and the contents aspirated after the procedure to document any esophageal surfactant administration.

Infants randomized to early CPAP will be managed according to unit practice for preterm infants on CPAP.

Caffeine Administration:

If randomized to LISA, caffeine will be given prior to the LISA procedure. In contrast, if randomized to CPAP, caffeine will be given soon after birth. If infants in the CPAP group meet intubation criteria, and the loading dose of caffeine has not been administered, to avoid delay in intubation, caffeine will be given no later than thirty minutes after intubation.

As an unblinded trial it is critical that both groups are standardized to avoid bias towards one arm for intubation/treatment failure. Therefore, strict delivery room/NICU criteria will be used.

In the Delivery Room, criteria for intubation will be as specified in the Neonatal Resuscitation Program guidelines (7th Ed) and will include:

  • Chest compressions
  • Ineffective respiration
  • Prolonged positive pressure ventilation (PPV)
  • Prolonged hypoxia

In the Neonatal Intensive Care Unit (NICU), randomized infants in both groups will only be intubated if they meet strict failure criteria :

  • CPAP level of 6-8 cmH2O and FiO2> 0.40 required to maintain oxygen saturation >90% for 2 hours after randomization
  • pH of 7.15 or less OR a partial pCO2 >65 mmHg on any (2) blood gas (arterial/capillary/ or venous) at least 2 hours after randomization in the first 72 hours of life.
  • Continued Apnea/Bradycardia/Desaturation events despite nasal intermittent minute ventilation (NIMV) mode of ventilation.

Infants intubated prior to randomization will be excluded. Infants not consented prior to birth will also be excluded to avoid bias in patient selection.

For pragmatic purposes sites will be able to use their standard approach for non-invasive ventilation (NCPAP or NIMV).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Premature infants born at 24 to 29+6 weeks gestation
  • Informed consent obtained (antenatal)
  • Infant is spontaneously breathing on CPAP of 5-8 cmH2O and maintaining a normal heart rate (HR>100 Bpm)

Exclusion criteria

  • Declined consent
  • Infants with known congenital anomalies
  • Unstable immediately after birth, requiring intubation in the delivery room

Treatment and study plan

Less Invasive Surfactant Administration LISA

Procedure

Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.

Continuous Positive Airway Pressure CPAP

Procedure

Infant will remain on CPAP Therapy during spontaneous respirations

Primary outcomes

  1. Frequency of subjects requiring endotracheal intubation between the two groups (LISA vs CPAP) in the first 72 hours of life

    Time frame: Within 72 hours of life

    Required intubation or meeting respiratory failure criteria of having a pCO2 greater than 65 mm Hg or an FiO2 greater than 0.4 for more than 2 hours in the first 72 hours of life

Secondary outcomes

  1. Duration of mechanical ventilation and/or CPAP

    Time frame: Through study completion at discharge, up to 6 months of corrected gestational age

    Number of days on mechanical ventilation and/or CPAP

  2. Oxygen at 36 weeks corrected age

    Time frame: Up to 40 weeks of corrected gestational age

    Requiring oxygen therapy greater than 0.21 at 36 weeks corrected age

  3. Frequency of Grade III and IV intraventricular hemorrhage

    Time frame: Through study completion at discharge, up to 6 months of corrected gestational age

    Intraventricular hemorrhage (grades 3-4)

  4. Neurodevelopment outcome at 24 months of corrected gestational age

    Time frame: Up to 2 years of corrected gestational age

    Neurodevelopmental assessments using the Bayley Scales of Infant Development 4th ed. will be done at 2 years of corrected corrected age (22-26 months) for subjects who were randomized at birth to receive surfactant by the LISA method versus CPAP alone.

  5. Neurodevelopment outcome at 2 Years of Age

    Time frame: 22-26 months corrected gestational age

    Overall and Domain Scores- Ages and Stages, 3rd ed. Questionnaire

  6. Need for repeat surfactant dosing

    Time frame: Up to 40 weeks of corrected gestational age

    Requiring more than one dose of surfactant

Other outcomes

  1. Laryngoscopy attempt with the LISA procedure

    Time frame: Number of laryngoscopy attempts per Surfactant dose, up to 36 weeks of corrected gestational age

    Total number of laryngoscopy attempts to administer surfactant via the LISA procedure

  2. Laryngoscopy attempt with endotracheal intubation

    Time frame: Number of laryngoscopy attempts per Surfactant dose, up to 36 weeks of corrected gestational age

    Total number of laryngoscopy attempts to administer surfactant via endotracheal intubation

Sponsors and collaborators

Lead sponsor

Sharp HealthCare

Other

Collaborators

  • Loma Linda University
  • Sharp Mary Birch Hospital for Women & Newborns
  • University of California, Irvine

Registry information

Official study title

A Multicenter, Randomized Trial of Preterm Infants Receiving Caffeine and Less Invasive Surfactant Administration Compared to Caffeine and Early Continuous Positive Airway Pressure (CaLI Trial)

Acronym: CaLI

Important dates

Study start
2020
Primary completion
2023
Study completion
2025
First posted
Dec 24, 2019
Registry last updated
Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.